vs

Side-by-side financial comparison of Axon Enterprise (AXON) and Lantheus Holdings, Inc. (LNTH). Click either name above to swap in a different company.

Axon Enterprise is the larger business by last-quarter revenue ($796.7M vs $406.8M, roughly 2.0× Lantheus Holdings, Inc.). Lantheus Holdings, Inc. runs the higher net margin — 13.3% vs 0.3%, a 13.0% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs 4.0%). Axon Enterprise produced more free cash flow last quarter ($155.4M vs $81.4M). Over the past eight quarters, Axon Enterprise's revenue compounded faster (31.5% CAGR vs 4.9%).

Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.

Lantheus Holdings, Inc. is a global healthcare firm specializing in the development, manufacturing and commercialization of innovative diagnostic imaging agents and related solutions. Its offerings cover core medical segments including oncology, cardiology and urology, with primary markets across North America and other key global regions.

AXON vs LNTH — Head-to-Head

Bigger by revenue
AXON
AXON
2.0× larger
AXON
$796.7M
$406.8M
LNTH
Growing faster (revenue YoY)
AXON
AXON
+34.9% gap
AXON
38.9%
4.0%
LNTH
Higher net margin
LNTH
LNTH
13.0% more per $
LNTH
13.3%
0.3%
AXON
More free cash flow
AXON
AXON
$74.0M more FCF
AXON
$155.4M
$81.4M
LNTH
Faster 2-yr revenue CAGR
AXON
AXON
Annualised
AXON
31.5%
4.9%
LNTH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXON
AXON
LNTH
LNTH
Revenue
$796.7M
$406.8M
Net Profit
$2.7M
$54.1M
Gross Margin
57.9%
59.2%
Operating Margin
-6.3%
19.0%
Net Margin
0.3%
13.3%
Revenue YoY
38.9%
4.0%
Net Profit YoY
-98.0%
558.8%
EPS (diluted)
$0.02
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXON
AXON
LNTH
LNTH
Q4 25
$796.7M
$406.8M
Q3 25
$710.6M
$384.0M
Q2 25
$668.5M
$378.0M
Q1 25
$603.6M
$372.8M
Q4 24
$573.4M
$391.1M
Q3 24
$544.3M
$378.7M
Q2 24
$504.1M
$394.1M
Q1 24
$460.7M
$370.0M
Net Profit
AXON
AXON
LNTH
LNTH
Q4 25
$2.7M
$54.1M
Q3 25
$-2.2M
$27.8M
Q2 25
$36.1M
$78.8M
Q1 25
$88.0M
$72.9M
Q4 24
$136.0M
$-11.8M
Q3 24
$67.0M
$131.1M
Q2 24
$40.8M
$62.1M
Q1 24
$133.2M
$131.1M
Gross Margin
AXON
AXON
LNTH
LNTH
Q4 25
57.9%
59.2%
Q3 25
60.1%
57.9%
Q2 25
60.4%
63.8%
Q1 25
60.6%
63.8%
Q4 24
60.5%
63.5%
Q3 24
60.8%
63.9%
Q2 24
60.3%
64.9%
Q1 24
56.4%
65.4%
Operating Margin
AXON
AXON
LNTH
LNTH
Q4 25
-6.3%
19.0%
Q3 25
-0.3%
11.4%
Q2 25
-0.2%
23.3%
Q1 25
-1.5%
27.4%
Q4 24
-2.6%
29.1%
Q3 24
4.4%
35.3%
Q2 24
6.5%
26.1%
Q1 24
3.5%
28.8%
Net Margin
AXON
AXON
LNTH
LNTH
Q4 25
0.3%
13.3%
Q3 25
-0.3%
7.2%
Q2 25
5.4%
20.8%
Q1 25
14.6%
19.6%
Q4 24
23.7%
-3.0%
Q3 24
12.3%
34.6%
Q2 24
8.1%
15.8%
Q1 24
28.9%
35.4%
EPS (diluted)
AXON
AXON
LNTH
LNTH
Q4 25
$0.02
$0.86
Q3 25
$-0.03
$0.41
Q2 25
$0.44
$1.12
Q1 25
$1.08
$1.02
Q4 24
$1.68
$-0.18
Q3 24
$0.86
$1.79
Q2 24
$0.53
$0.88
Q1 24
$1.73
$1.87

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXON
AXON
LNTH
LNTH
Cash + ST InvestmentsLiquidity on hand
$1.7B
$359.1M
Total DebtLower is stronger
$1.8B
$568.7M
Stockholders' EquityBook value
$3.2B
$1.1B
Total Assets
$7.0B
$2.2B
Debt / EquityLower = less leverage
0.56×
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXON
AXON
LNTH
LNTH
Q4 25
$1.7B
$359.1M
Q3 25
$2.4B
$382.0M
Q2 25
$2.1B
$695.6M
Q1 25
$2.2B
$938.5M
Q4 24
$788.1M
$912.8M
Q3 24
$1.0B
$866.4M
Q2 24
$968.9M
$757.0M
Q1 24
$964.1M
$718.3M
Total Debt
AXON
AXON
LNTH
LNTH
Q4 25
$1.8B
$568.7M
Q3 25
$2.0B
$567.9M
Q2 25
$2.0B
$566.8M
Q1 25
$2.0B
$566.1M
Q4 24
$680.3M
$565.3M
Q3 24
$613.0K
Q2 24
$563.2M
Q1 24
$562.5M
Stockholders' Equity
AXON
AXON
LNTH
LNTH
Q4 25
$3.2B
$1.1B
Q3 25
$3.0B
$1.1B
Q2 25
$2.7B
$1.2B
Q1 25
$2.6B
$1.2B
Q4 24
$2.3B
$1.1B
Q3 24
$2.1B
$1.2B
Q2 24
$1.9B
$1.0B
Q1 24
$1.8B
$945.5M
Total Assets
AXON
AXON
LNTH
LNTH
Q4 25
$7.0B
$2.2B
Q3 25
$6.7B
$2.3B
Q2 25
$6.2B
$2.1B
Q1 25
$6.1B
$2.1B
Q4 24
$4.5B
$2.0B
Q3 24
$4.0B
$2.0B
Q2 24
$3.7B
$1.9B
Q1 24
$3.6B
$1.8B
Debt / Equity
AXON
AXON
LNTH
LNTH
Q4 25
0.56×
0.52×
Q3 25
0.66×
0.51×
Q2 25
0.73×
0.49×
Q1 25
0.79×
0.49×
Q4 24
0.29×
0.52×
Q3 24
0.00×
Q2 24
0.55×
Q1 24
0.59×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXON
AXON
LNTH
LNTH
Operating Cash FlowLast quarter
$217.2M
$90.2M
Free Cash FlowOCF − Capex
$155.4M
$81.4M
FCF MarginFCF / Revenue
19.5%
20.0%
Capex IntensityCapex / Revenue
7.8%
2.2%
Cash ConversionOCF / Net Profit
79.14×
1.67×
TTM Free Cash FlowTrailing 4 quarters
$75.1M
$354.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXON
AXON
LNTH
LNTH
Q4 25
$217.2M
$90.2M
Q3 25
$60.0M
$105.3M
Q2 25
$-91.7M
$87.1M
Q1 25
$25.8M
$107.6M
Q4 24
$250.2M
$157.7M
Q3 24
$91.3M
$175.1M
Q2 24
$82.8M
$84.7M
Q1 24
$-15.9M
$127.2M
Free Cash Flow
AXON
AXON
LNTH
LNTH
Q4 25
$155.4M
$81.4M
Q3 25
$33.4M
$94.7M
Q2 25
$-114.7M
$79.1M
Q1 25
$932.0K
$98.8M
Q4 24
$225.4M
$141.4M
Q3 24
$64.8M
$159.3M
Q2 24
$71.4M
$73.5M
Q1 24
$-32.1M
$119.0M
FCF Margin
AXON
AXON
LNTH
LNTH
Q4 25
19.5%
20.0%
Q3 25
4.7%
24.7%
Q2 25
-17.2%
20.9%
Q1 25
0.2%
26.5%
Q4 24
39.3%
36.1%
Q3 24
11.9%
42.0%
Q2 24
14.2%
18.7%
Q1 24
-7.0%
32.2%
Capex Intensity
AXON
AXON
LNTH
LNTH
Q4 25
7.8%
2.2%
Q3 25
3.7%
2.8%
Q2 25
3.4%
2.1%
Q1 25
4.1%
2.3%
Q4 24
4.3%
4.2%
Q3 24
4.9%
4.2%
Q2 24
2.2%
2.8%
Q1 24
3.5%
2.2%
Cash Conversion
AXON
AXON
LNTH
LNTH
Q4 25
79.14×
1.67×
Q3 25
3.79×
Q2 25
-2.54×
1.11×
Q1 25
0.29×
1.47×
Q4 24
1.84×
Q3 24
1.36×
1.34×
Q2 24
2.03×
1.36×
Q1 24
-0.12×
0.97×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXON
AXON

Software And Sensors Segment$342.5M43%
TASER Devices Professional$264.2M33%
Personal Sensors$109.1M14%
Platform Solutions$80.9M10%

LNTH
LNTH

Radiopharmaceutical Oncology$240.2M59%
Definity$85.3M21%
Strategic Partnerships And Other$23.3M6%
Techne Lite$21.0M5%
Licenseand Royalty Revenues$17.4M4%
Other$13.6M3%
Other Precision Diagnostics$5.9M1%

Related Comparisons